ephrin-B2 Inhibitors
Ephrin-B2 inhibitors are a class of small molecules and antibodies that target ephrin-B2, a member of the ephrin family of receptor tyrosine kinase ligands. Ephrin-B2 plays a significant role in cell signaling and cell-cell interactions, particularly in the development and maintenance of tissues and organs, such as the nervous and cardiovascular systems. These inhibitors are designed to modulate the activity of ephrin-B2 and its corresponding Eph receptors, which are transmembrane receptor kinases. By interfering with the interaction between ephrin-B2 and its receptors, these inhibitors can disrupt cellular processes that rely on ephrin-B2 signaling.
The applications of ephrin-B2 inhibitors are diverse, including basic research to understand the complex signaling pathways in development and disease. Additionally, ephrin-B2 inhibitors may have implications in regenerative medicine and tissue engineering by controlling cell behavior and tissue organization. Researchers continue to explore and refine these compounds to harness their abilities for various biological and medical applications.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Neratinib | 698387-09-6 | sc-364549 sc-364549A sc-364549B sc-364549C sc-364549D | 5 mg 25 mg 100 mg 500 mg 1 g | $90.00 $210.00 $375.00 $740.00 $1225.00 | 4 | |
Neratinib, a tyrosine kinase inhibitor, targets ErbB family receptors, affecting downstream signaling pathways such as MAPK and PI3K-Akt. Inhibition of these pathways may indirectly modulate ephrin-B2, which is involved in cellular processes influenced by ErbB signaling. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, a pathway implicated in ephrin-B2 expression. By blocking NF-κB, this inhibitor may disrupt the signaling cascades leading to ephrin-B2 modulation. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $56.00 $130.00 | 27 | |
SU6656, a Src family kinase inhibitor, can potentially influence ephrin-B2 by targeting Src kinase, a component of the Eph receptor signaling pathway. Ephrin-B2 modulation may result from the inhibition of Src-dependent signaling cascades. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y27632, a selective Rho-associated protein kinase (ROCK) inhibitor, can impact cellular cytoskeleton dynamics. Since ephrin-B2 signaling involves cytoskeletal rearrangements, inhibition of ROCK by Y27632 may indirectly affect ephrin-B2 modulation by disrupting cytoskeletal-dependent cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can potentially influence ephrin-B2 by targeting the JNK signaling pathway. Ephrin-B2 expression may be modulated indirectly through the inhibition of JNK-mediated signaling cascades. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. By targeting Src kinase, which is involved in Eph receptor signaling pathways, PP2 may indirectly modulate ephrin-B2 expression and cellular processes influenced by Eph receptor activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that can potentially impact ephrin-B2 by targeting the MAPK/ERK pathway. Ephrin-B2 modulation may occur indirectly through the disruption of MAPK/ERK signaling cascades, which play a role in cellular processes influenced by Eph receptor activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that can potentially influence ephrin-B2 by targeting the PI3K-Akt pathway. Ephrin-B2 modulation may result from the disruption of PI3K-Akt signaling cascades, which play a role in cellular processes influenced by Eph receptor activation. | ||||||
GSK1838705A | 1116235-97-2 | sc-364502 sc-364502A | 5 mg 50 mg | $240.00 $992.00 | ||
GSK1838705A is an IGF-1R inhibitor, potentially influencing ephrin-B2 through the IGF-1R signaling pathway. Ephrin-B2 modulation may occur indirectly through the inhibition of IGF-1R-mediated signaling cascades, which are interconnected with pathways influenced by Eph receptor activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that may impact ephrin-B2 by targeting the p38 MAPK signaling pathway. Ephrin-B2 modulation may result from the disruption of p38 MAPK signaling cascades, which play a role in cellular processes influenced by Eph receptor activation. | ||||||